What is Leerink Partnrs’ Forecast for TNDM FY2028 Earnings?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) – Analysts at Leerink Partnrs dropped their FY2028 earnings per share (EPS) estimates for Tandem Diabetes Care in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical device company will post earnings of $0.00 per share for the year, down from their previous forecast of $0.01. The consensus estimate for Tandem Diabetes Care’s current full-year earnings is ($1.73) per share.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its earnings results on Wednesday, November 6th. The medical device company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.08. The company had revenue of $243.97 million during the quarter, compared to analyst estimates of $224.14 million. Tandem Diabetes Care had a negative return on equity of 44.19% and a negative net margin of 14.84%. The business’s revenue was up 31.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.38) EPS.

Other research analysts have also issued reports about the stock. Royal Bank of Canada started coverage on shares of Tandem Diabetes Care in a report on Wednesday, October 2nd. They issued an “outperform” rating and a $65.00 price target for the company. UBS Group raised Tandem Diabetes Care to a “hold” rating in a report on Friday, August 2nd. Wells Fargo & Company increased their price target on Tandem Diabetes Care from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler restated an “overweight” rating and set a $55.00 price objective (up previously from $50.00) on shares of Tandem Diabetes Care in a research report on Friday, August 2nd. Finally, Canaccord Genuity Group initiated coverage on Tandem Diabetes Care in a research report on Thursday, August 8th. They issued a “buy” rating and a $57.00 target price on the stock. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $54.25.

Tandem Diabetes Care Stock Performance

Tandem Diabetes Care stock opened at $30.42 on Tuesday. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care has a 12 month low of $18.45 and a 12 month high of $53.69. The company has a fifty day moving average price of $36.16 and a two-hundred day moving average price of $41.23. The company has a market cap of $2.00 billion, a PE ratio of -16.19 and a beta of 1.36.

Insider Activity

In other Tandem Diabetes Care news, Director Kim D. Blickenstaff sold 10,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the sale, the director now directly owns 195,190 shares in the company, valued at approximately $5,855,700. The trade was a 4.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Tandem Diabetes Care

Large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Tandem Diabetes Care by 0.4% during the first quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock valued at $249,732,000 after purchasing an additional 30,664 shares during the last quarter. State Street Corp increased its holdings in shares of Tandem Diabetes Care by 3.2% in the third quarter. State Street Corp now owns 2,655,736 shares of the medical device company’s stock valued at $112,630,000 after buying an additional 83,172 shares in the last quarter. Fred Alger Management LLC increased its holdings in shares of Tandem Diabetes Care by 45.2% in the second quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company’s stock valued at $87,595,000 after buying an additional 677,036 shares in the last quarter. Bellevue Group AG lifted its position in shares of Tandem Diabetes Care by 19.9% during the 3rd quarter. Bellevue Group AG now owns 1,850,891 shares of the medical device company’s stock valued at $78,496,000 after acquiring an additional 307,624 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Tandem Diabetes Care by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,525,816 shares of the medical device company’s stock worth $64,722,000 after acquiring an additional 18,187 shares in the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.